References
- Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Oprs. 2007;23(1);63–65.
- Garbaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Oprs. 2007;23(1);62–63.
- Saint-Jean A, Sainz De La Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Am Acad Ophthalmol. 2012;119(9);1798–1802.
- Vinod K, Diaz V. Use of amniotic membrane graft in the surgical management of cicatricial ectropion associated with cetuximab therapy. J Surg Case Rep. 2015;1;1–3.
- Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3);515–521.
- Frankfort BJ, Garibaldi DC. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit egfr signaling. Ophthal Plast Reconstr Surg. 2007;23(6);496–497.
- Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 2007;23;65–66.
- Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea. 2009;28(6);706–707.
- Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008;27(5);612–614.
- Morris LGT, Hochster HS, DeLacure MD. Eyelash trichomegaly secondary to panitumumab therapy. Curr Oncol. 2011;18(3);145–146.
- Holcmann M, Silbilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4)e1004969.
- Gracitelli C, Osaki TH, Valdrighi NY, Viana G, Osaki M. Cicatricial ectropion secondary to psoriatic arthritis. Case Rep Ophthalmol Med. 2015;article ID 315465;3.
- Kopsachilis N, Tsaousis KT, Tourtas T, Tsinopoulos IT. Severe Chronic Blepharitis and Scarring Ectropion Associated with Discoid Lupus Erythematosus. Clin Exp Optom. 2013 Jan;96(1);124–125.
- Mitchell EP, Lacouture M, Shearer H, et al. A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT as 2nd-line treatment (tx): interim analysis. J Clin Oncol. 2008;26(Suppl 15) ; 15007.
- Mitchell EP, Lacouture M, Shearer H, et al. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for Panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2009;27(18S)CRA4027.